Active, not recruitingPhase 2NCT04517851

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Prithviraj Bose, MD
M.D. Anderson Cancer Center
Intervention
Elotuzumab(biological)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
2021 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04517851 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials